accountbiotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account